EBIT: Income before interest and taxes.
Intellia Therapeutics, Inc. (NTLA) had EBIT of $-440.99M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$67.67M |
|
$-412.69M |
|
-- |
|
$67.67M |
|
$508.66M |
|
$-440.99M |
|
$28.30M |
|
$-412.69M |
|
$-412.69M |
|
$-412.69M |
|
$-412.69M |
|
$-412.69M |
|
$-412.69M |
|
|
EBIT |
$-440.99M |
$-425.07M |
|
108.38M |
|
108.38M |
|
$-3.81 |
|
$-3.81 |
|
| Balance Sheet Financials | |
$527.71M |
|
$17.67M |
|
$314.42M |
|
$842.13M |
|
$103.88M |
|
-- |
|
$66.85M |
|
$170.73M |
|
$671.39M |
|
$671.39M |
|
$671.39M |
|
116.32M |
|
| Cash Flow Statement Financials | |
$-394.74M |
|
$228.03M |
|
$131.49M |
|
$202.79M |
|
$167.57M |
|
$-35.22M |
|
$80.22M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.08 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-651.67% |
|
-651.67% |
|
-628.14% |
|
-609.85% |
|
-609.85% |
|
$-395.87M |
|
-- |
|
-- |
|
-- |
|
0.08 |
|
-- |
|
7.15 |
|
51.07 |
|
-61.47% |
|
-61.47% |
|
-49.01% |
|
-61.47% |
|
$5.77 |
|
$-3.65 |
|
$-3.64 |
|